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Antenatal Bartter syndrome is an autosomal recessive
disorder caused by loss-of-function mutations in genes
encoding for the renal outer medullary potassium channel
(RomK) or the sodium–potassium-2-chloride co-transporter
(NKCC2) [1]. Given that NKCC2 is sensitive to inhibition
by furosemide and requires RomK for proper functioning,
defects in either transport protein severely impair salt
reabsorption in the thick ascending loop of Henle, thereby
mimicking chronic administration of furosemide. Apart
from the occurrence of transient hyperkalemia in patients
with mutant RomK, which reflects their requirement to
secrete potassium into the urine by the distal tubules, the
phenotypes of NKCC2- and RomK-deficient patients are
undistinguishable: polyuria shortly after birth with
isosthenuria, excessive renal prostaglandin E2 production,
and hyper-reninism with hypokalemic alkalosis.
Fluid losses in affected patients can be life-threatening
and are managed with compensation of urinary losses of
water and electrolytes. This approach may actually aggra-
vate the polyuria, resulting in a total fluid intake of up to
50 ml/kg/h, which equals 1 liter of fluid per day in a 1-kg
patient [1]. Because the oral administration of such large
quantities of fluids is technically challenging in premature
babies, non-steroidal anti-inflammatory drugs (NSAID),
such as indomethacin, are routinely administered to reduce
diuresis and saluresis [1]. NSAID inhibit prostaglandin
production by blocking the enzymatic activity of cyclo-
oxygenase (COX). COX exists as two unique isoforms,
namely, COX-1, which is expressed constitutively in the
renal vasculature and in principal cells of the collecting
duct, and COX-2, which is an inducible enzyme whose
renal expression is restricted to a few cells of the macula
densa and the vasculature. In states of salt and or volume
depletion, COX-2 expression is significantly up-regulated
in cells of the macula densa through a mechanism by which
low intracellular chloride levels induce COX-2 via p38
MAPK. Consistent with its renal induction, COX-2-
selective NSAID have been demonstrated to be as effective
as the unselective NSAID indomethacin in reducing
polyuria in patients with antenatal Bartter syndrome [2].
These data prove that COX-2 plays a key role in the
signaling cascade leading to polyuria in antenatal Bartter
syndrome.
Inhibition of COX-2 also reduces hyper-reninism and
hypokalemia in patients with antenatal Bartter syndrome.
This effect should actually further aggravate salt loss
secondary to decreased angiotensin II and aldosterone
levels; therefore, other means of salt conservation must
exist. First, COX-2-derived prostaglandin E2 production
has direct diuretic effects. Various prostaglandin E2 recep-
tors are expressed in the renal tubules, and these have been
implicated in this phenomenon; however, their precise
contributions remain unclear. Second, both COX-2-
selective NSAID and -unselective NSAID reduce the
glomerular filtration rate, thereby further reducing renal
salt and water losses. Collectively, the salt-retaining tubular
and vascular effects of NSAID obviously dominate over the
salt loss resulting from the reduced angiotensin II and
aldosterone levels.
Even though robust evidence from animal and human
studies proves a key role of COX-2 in the pathophysiology
of antenatal Bartter syndrome, only rofecoxib, a highly
selective COX-2 inhibitor whose use had to be discon-
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reported as a therapeutic modality in a single infant with an
extreme variant of antenatal Bartter syndrome [3]. The
argument that avoidance of COX-2-selective inhibitors
might be due to the requirement of COX-2 activity for
normal glomerular development up to the 34th week of
gestation can readily be discarded by the fact that
unselective NSAID, such as indomethacin, also exert their
beneficial effects in antenatal Bartter syndrome by inhibiting
COX-2. However, avoidance of COX-2-selective NSAID is
probably prudent given our lack of experience with these
drugs in neonates.
The best reason in favor of using traditional NSAID,
such as indomethacin, as standard drugs in treating
antenatal Bartter syndrome is the solid body of clinical
experience accumulated in using this drug to treat numerous
premature neonates drug to promote closure of an open ductus
arteriosus. Although necrotizing enterocolitis has been
reported in premature babies treated with indomethacin, it is
difficult to conclude that this is causally related to indometh-
acin given the relatively high incidence of necrotizing
enterocolitis in premature babies.
From a pharmacological point of view, the use of
indomethacin instead of aspirin is much more plausible
because the relative COX-2 selectivity of indomethacin
in vivo is roughly 20-fold higher than that of aspirin [4].
In other words, equal inhibition of COX-2 by aspirin (as
compared with indomethacin) will result in a much more
profound—but unnecessary—inhibition of COX-1 in
platelets and the intestinal mucosa, thereby potentially
causing severe bleeding disorders and gastrointestinal
side effects.
Finally, it appears counterintuitive to treat preterm
neonates with aspirin while the Federal Drug Administra-
tion (as requested by the American Association of
Pediatrics) requires manufacturers of aspirin to label their
products with a warning that this drug may trigger Reye’s
syndrome in children. This warning also applies to the
patient described in the case report, especially when
considering that treatment with NSAID is continued well
beyond infancy, thus placing the child at an avoidable risk
for Reye’s syndrome.
Taken together, it does not come as a surprise that aspirin
reduces polyuria and loss of electrolytes in a patient likely
to be affected by antenatal Bartter syndrome because
aspirin also inhibits COX-2. It is, however, somewhat
questionable to base a therapeutic decision solely on an
assumption (i.e., the risk of necrotizing enterocolitis is
greater with indomethacin than with aspirin) despite a clear
warning of the American Association of Pediatrics
concerning the use of aspirin in children while reasonably
well-studied drugs are available for neonatal patients.
This case report underscores once more the need for
controlled trials or at least registries when it comes to
treating rare diseases.
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